Amir M, Agarwal H K
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hamdard University, New Delhi, India.
Pharmazie. 2005 Aug;60(8):563-70.
Cyclooxygenase-2 (COX-2) is an enzyme induced by inflammatory and mitogenic stimuli and results in enhanced synthesis of PGs in inflamed and neoplastic tissues. It is associated with cell proliferation and growth, in various cancerous conditions. We review the potential mechanisms of cancer reduction with COX-2 inhibitors and the preclinical evidence suggesting their effectiveness. Results of our study show that COX-2 is a regulatory factor for a number of pathways that can result in cancer. COX-2 makes cells resistant to apoptosis and promote angiogenesis, metastasis and cancer cell cycle by controlling number of targets. We found that, COX-2 selective inhibitors (like celecoxib and NS-398) can suppress the cancer both by COX-2 dependent and COX-2 independent pathways. COX-2 inhibitors can also produce synergic effects when used with other anti-cancer therapies. Thus, it is concluded that COX-2 selective inhibitors may be promising agents for prevention and treatment of cancer.
环氧化酶-2（COX-2）是一种由炎症和促有丝分裂刺激诱导产生的酶，可导致炎症组织和肿瘤组织中前列腺素（PGs）的合成增加。在各种癌症情况下，它与细胞增殖和生长相关。我们综述了COX-2抑制剂降低癌症风险的潜在机制以及提示其有效性的临床前证据。我们的研究结果表明，COX-2是许多可导致癌症的信号通路的调节因子。COX-2通过控制多个靶点，使细胞对凋亡产生抗性，并促进血管生成、转移和癌细胞周期。我们发现，COX-2选择性抑制剂（如塞来昔布和NS-398）可通过COX-2依赖性和COX-2非依赖性途径抑制癌症。COX-2抑制剂与其他抗癌疗法联合使用时也可产生协同效应。因此，得出结论，COX-2选择性抑制剂可能是预防和治疗癌症的有前景的药物。
